2cureX AB (publ) (STO:2CUREX)
Sweden · Delayed Price · Currency is SEK 1.700
-0.060 (-3.41%)
Jun 11, 2026, 3:39 PM CET
2cureX AB Company Description
2cureX AB (publ) operates as a medical technology company in Europe.
Its proprietary IndiTreat test family creates various 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are effective for that specific tumor.
2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden.
2cureX AB (publ)
| Country | Sweden |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Nathaniel Hutley |
Contact Details
Address: Lilla Strandgatan 19, 261 29 Landskrona , 261 29 Sweden | |
| Phone | 45 22 11 53 99 |
| Website | 2curex.se |
Stock Details
| Ticker Symbol | 2CUREX |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0010468124 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Nathaniel Hutley | Interim Chief Executive Officer and Director |
| Ole Thastrup VD | Co-Founder and Chairman |
| Grith Hagel | Co-Founder, Vice President of Innovation and Director |
| Kenneth Graabek Johansen | Chief Financial Officer |
| Jacob Thastrup | Chief Technology Officer |
| Manuel Fernandez | Director Quality and Regulatory Affairs |